Berger Montague Alerts LifeMD Investors About Class Action Deadline and Lawsuit

A significant development has emerged for investors of LifeMD, Inc. (NASDAQ: LFMD). National plaintiffs' law firm Berger Montague PC has made an announcement regarding a class action lawsuit against the company. This action affects those who purchased or acquired LifeMD shares between May 7, 2025, and August 5, 2025. All concerned investors should take note of the imminent deadline to claim their rights as lead plaintiffs in this case.

Understanding the Lawsuit Against LifeMD

The lawsuit primarily accuses LifeMD of overstating its position in the market and providing financial guidance for 2025 that lacked realism. According to the complaint, LifeMD did not disclose crucial information about its rising customer acquisition costs, particularly related to its RexMD platform, which might have hampered its credibility. Additionally, the lawsuit highlights the company's push for obesity treatment medications like Wegovy and Zepbound, indicating that LifeMD's communications during the class period were misleading and lacking a solid foundation.

The nature of these allegations means that many investors who relied on LifeMD's public statements may now find themselves facing substantial financial losses. As the market eventually revealed the true state of LifeMD's business practices, many investors experienced significant declines in the value of their holdings.

Key Details for Affected Investors

Investors who acquired securities in LifeMD during the specified class period should act promptly. To secure your position as a lead plaintiff representative of the class, you have until October 27, 2025, to file your claim. The importance of this action cannot be overstated. In many cases, being appointed as a lead plaintiff allows investors to have a more significant role in the legal proceedings.

If you're an investor wishing to know your options, click here for more information on how to proceed with filing your claim. For personal inquiries, reach out to Andrew Abramowitz, of Berger Montague, at (215) 875-3015 or via email at [email protected] Additionally, Caitlin Adorni is available at (267) 764-4865 or [email protected] for further assistance.

About LifeMD and Its Operations

LifeMD is based in New York and specializes in providing virtual medical services alongside prescription delivery. The firm's business model relies heavily on the modern approach to healthcare, which merges telehealth services with e-pharmacy options. Unfortunately, the allegations raise questions about the underlying viability and honesty of LifeMD's operational strategy.

While the firm purportedly positions itself as a leader in delivering accessible healthcare, the implications of the current lawsuit could critically affect its reputation and operational integrity. Investors will be watching closely as the case unfolds, particularly to see how the legal proceedings may influence LifeMD's market performance and stock valuation.

Conclusion

Amidst the ongoing litigation, it's crucial for LifeMD investors to stay informed and engaged with this timely matter. With a looming deadline for filing claims, prospective lead plaintiffs should assess their options wisely. Berger Montague has a long history in securities class action litigation, providing representation for individual and institutional investors since 1970. This establishes the firm as a credible advocate for current and former shareholders seeking redress for perceived injustices in their investments.

For up-to-date information on the matter, continue to follow developments closely. This situation serves as a reminder of the risks associated with investing and the importance of due diligence.